chartexchange

Zhengye First-Half Revenue Falls 18.3% as Net Loss Narrows

Securities.io | Nov 12, 2026 6:07 PM EST

Zhengye Biotechnology Holding Limited reported first-half revenue of RMB50.9 million (US$7.5 million) in a filing dated November 12, 2026, down 18.3% from a year earlier, as customer losses and cost cutting reduced vaccine sales. Net loss at the Chinese veterinary vaccine maker narrowed to RMB22.2 million from RMB25.6 million for the six months ended June 30, 2026, as lower operating expenses partly offset weaker sales. Customer Cutbacks Reshape Vaccine Sales Management attributed the decline…

Read original article